You are here: Industry Insights > Tenapanor

News List

Ardelyx Announces NDA Acceptance of Tenapanor americanpharmaceuticalreview
September 22, 2020
Ardelyx announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
Ardelyx Submits NDA for Tenapanor americanpharmaceuticalreview
July 10, 2020
Ardelyx announced the submission of a New Drug Application (NDA) for tenapanor to the U.S. Food and Drug Administration (FDA) for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
FDA Approves Ibsrela (tenapanor) for the Treatment of Irritable Bowel Syndrome with Constipation drugs
September 16, 2019
Ardelyx, Inc. announced that the U.S. Food and Drug Administration has approved Ibsrela (tenapanor), a 50 mg, twice daily oral pill for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Ardelyx’s first-in-class NHE3 blocker Tenapanor boasts positive phase III data pharmaceutical-technology
May 27, 2017
On May 12, Ardelyx announced positive top-line results from the T3MPO-1 Phase III study for the use of tenapanor to treat patients with constipation predominant Irritable Bowel Syndrome (IBS-C).
Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C americanpharmaceuticalreview
May 15, 2017
Ardelyx reported positive, topline results from the T3MPO-1 trial, the first of two Phase 3 trials evaluating tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).